Navigation Links
Scripps Research announces research & license agreement with Janssen Pharmaceuticals
Date:5/7/2013

LA JOLLA, CA May 7, 2013 The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. Under the agreement Janssen will receive certain license rights to the results of the research. Janssen Pharmaceuticals will collaborate in the research on influenza through its Crucell Vaccine Institute.

"We're delighted to partner with Janssen in this work that could have a significant impact on human health," said Michael A. Marletta, president and CEO of TSRI. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."

Scott Forrest, TSRI's vice president for business development, added, "This deal is the latest example of our corporate partnership strategy, in which we seek focused collaborations to match companies' specific areas of interest with areas of expertise among multiple TSRI labs."

The new agreement builds on research on the influenza virus conducted jointly by TSRI and Janssen's Crucell Vaccine Institute. Previous collaborations have resulted in several high-impact publications, most recently in August 2012 in the journal Science.

Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in the United States, according to estimates by the U.S. Centers for Disease Control. Pandemics pose a greater dangerthe Spanish Flu of 1918-1919 may have killed 50 million people worldwide.

The new strategic collaboration with Janssen follows TSRI's announcement of a five-year agreement with Bristol-Myers Squibb last June; that agreement covered the development of chemistry methodologies and related work.

Forrest notes that promising future areas for corporate partnerships at TSRI include Oncology, Neurodegeneration and Immunology.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
3. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
4. Scripps Research Institute scientists develop antidote for cocaine overdose
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
7. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
8. Scripps Florida scientists identify neurotranmitters that lead to forgetting
9. Plastic trash altering ocean habitats, Scripps study shows
10. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
11. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... June 23, 2020 , ... In its June 22 online post, ... Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company ... on June 16 that starting July 5 it would begin offering free ...
(Date:6/19/2020)... ... June 18, 2020 , ... Join experts from Envigo Lauren ... a live webinar on Wednesday, July 8, 2020 at 11am EDT (4pm ... genetically engineer new models. However, while modifying the genome may be more straightforward, the ...
(Date:6/11/2020)... ... 09, 2020 , ... Superior Controls, Inc. , an E Technologies Company ... the life sciences industry, is pleased to announce the recent hiring of Ray Boudreau, ... Seabrook, New Hampshire office. In his new role, Boudreau will use his extensive ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, the one ... includes buy three, get the fourth unit free with no limit on the ... known as exosomes, have been a game changer for regenerative therapies. The products ...
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis Therapeutics, ... that it has filed an Investigational New Drug application (IND) with the U.S. ... its lead drug candidate NBTX-001 in patients with panic disorder (PD). , "Adding ...
(Date:6/11/2020)... ... June 08, 2020 , ... Greffex, ... through the use of proprietary clean viral vectors, recently announced a key manufacturing ... Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) ...
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... ... the release of the NEON Micro-Tracer Solution, a highly accurate, contact ... COVID-19 virus in the workplace. Contact tracing, a core disease control measure, is ...
Breaking Biology Technology: